C

Colinz Laboratories Ltd
BSE:531210

Watchlist Manager
Colinz Laboratories Ltd
BSE:531210
Watchlist
Price: 55.5 INR 20%
Market Cap: ₹139.9m

Operating Margin

4%
Current
Declining
by 2%
vs 3-y average of 6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
4%
=
Operating Income
₹2.3m
/
Revenue
₹58.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
4%
=
Operating Income
₹2.3m
/
Revenue
₹58.7m

Peer Comparison

Country Company Market Cap Operating
Margin
IN
Colinz Laboratories Ltd
BSE:531210
116.5m INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
223.2B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.1B EUR
Loading...

Market Distribution

In line with most companies in India
Percentile
35th
Based on 5 437 companies
35th percentile
4%
Low
-153 833.3% — 2.7%
Typical Range
2.7% — 13.2%
High
13.2% — 9 977%
Distribution Statistics
India
Min -153 833.3%
30th Percentile 2.7%
Median 7.3%
70th Percentile 13.2%
Max 9 977%

Colinz Laboratories Ltd
Glance View

Market Cap
139.9m INR
Industry
Pharmaceuticals

Colinz Laboratories Ltd. engages in the manufacture of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectable, ointments, and creams. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-01-13. The firm operates and supplies medicines in the domestic market. The Company’s products include oncology, ayurvedic and nutraceuticals. Its oncology products include imatinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim and pegylated liposome doxorubicin. Its ayurvedic products include anti-diarrheas, anti-pyrectics, anti-inflammatories, anti-spasmodic, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonic, ulcer healing agents, digestive agents, drugs to treat oligospermia and erectile dysfunction, ear drops, uterine tonic, anti-diabetics, and general tonics.

COLINZ Intrinsic Value
27.06 INR
Overvaluation 51%
Intrinsic Value
Price
C
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
4%
=
Operating Income
₹2.3m
/
Revenue
₹58.7m
What is Colinz Laboratories Ltd's current Operating Margin?

The current Operating Margin for Colinz Laboratories Ltd is 4%, which is below its 3-year median of 6%.

How has Operating Margin changed over time?

Over the last 3 years, Colinz Laboratories Ltd’s Operating Margin has decreased from 6.1% to 4%. During this period, it reached a low of 4% on Oct 30, 2025 and a high of 7% on Mar 31, 2023.

Back to Top